SCHEDULE: Vestal Point Capital Reduces Tyra Biosciences Stake Below 5%

Vestal Point Capital and Ryan Wilder have filed an amendment to their Schedule 13G, reporting a reduced beneficial ownership of 4.5% in Tyra Biosciences, Inc. as of September 30, 2025.

Summary

• Vestal Point Capital, LP and Ryan Wilder have amended their beneficial ownership report for Tyra Biosciences, Inc., now holding 2,425,000 shares of Common Stock.
• This represents a 4.5% stake in the company, indicating a reduction from a previous beneficial ownership position that was 5% or greater.
• The calculation is based on 53,297,140 shares of Common Stock outstanding as of August 11, 2025, as reported in the Company's Quarterly Report on Form 10-Q.
• The reporting persons maintain shared voting and dispositive power over all beneficially owned shares.
• The investment is stated to be for ordinary course of business purposes, without intent to influence company control.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in a significant institutional stake below the 5% threshold, which could imply a less favorable view from the investor, although the filing itself is a neutral regulatory disclosure.

Positives

• NA This filing is a disclosure of beneficial ownership and does not contain information on company performance or positive developments.

Negatives

• A reduction in beneficial ownership from above 5% to 4.5% by a significant institutional investor like Vestal Point Capital could be interpreted as a cautious signal regarding their investment thesis or portfolio strategy.

Risks

• NA This Schedule 13G filing primarily reports beneficial ownership and does not detail specific risks related to Tyra Biosciences, Inc.'s operations or financial health.

Future Outlook

NA This Schedule 13G filing does not provide forward-looking statements or guidance from the issuer.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

NA This filing is a disclosure of beneficial ownership and does not provide analysis of broader industry trends or competitors.

Comparison to Industry Standards

• NA This filing does not provide information for comparison to industry benchmarks or specific comparable companies/projects.

Management Changes

Corporate Governance

Legal Proceedings

• NA This filing does not report any litigation or regulatory matters concerning the issuer.

Related Party Transactions

• NA This filing does not disclose any related party dealings.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional stake might lead to increased scrutiny or a negative perception of the company's prospects among other investors, potentially influencing trading behavior.

Next Steps

• NA This filing does not outline future actions, events, or milestones for the issuer or the reporting persons beyond the regulatory disclosure itself.

Key Dates

Recommendation

The filing indicates that Vestal Point Capital, a significant institutional investor, has reduced its stake in Tyra Biosciences, Inc. from above 5% to 4.5%. While not a complete exit, this reduction below the 5% threshold could signal a re-evaluation of the investment thesis or portfolio rebalancing. Investors should exercise caution and monitor further developments, warranting a 'hold' recommendation rather than a 'buy' or 'strong sell' based solely on this disclosure.

Keywords

Tyra Biosciences, Vestal Point Capital, Ryan Wilder, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, SEC Filing